Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOFIVA GENOMICS Co has the GF Score of 68, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes SOFIVA GENOMICS Co
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
SOFIVA GENOMICS Co (ROCO:6615) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
SOFIVA GENOMICS Co GF Score Related Terms
ROCO:6615 vs TMO, DHR, IDXX: GF Score Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co GF Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's GF Score distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's GF Score falls into.
SOFIVA GENOMICS Co (ROCO:6615) has a GF Score of 68 as of Jul. 23, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SOFIVA GENOMICS Co and its competitors. This is near median its historical median of 63.00. Over the past decade, SOFIVA GENOMICS Co's GF Score has ranged from 16.00 to 80.00.
Is SOFIVA GENOMICS Co's GF Score too high?
SOFIVA GENOMICS Co's current GF Score of 68 is near median its 10-year median of 63.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 80.00. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's GF Score compare to TMO and DHR?
SOFIVA GENOMICS Co's GF Score of 68 can be compared against companies in the Medical Diagnostics & Research industry. Historically, SOFIVA GENOMICS Co's own GF Score has ranged from 16.00 to 80.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current GF Score is 68, which is near median its own 10-year median of 63.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$30.93, compared to a current price of NT$34.90 — trading 12.8% above its estimated fair value. The current GF Score is 68, which is near median its 10-year median of 63.00. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current GF Score is 68 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$34.90 is trading 12.8% above its estimated GF Value™ of NT$30.93.
GuruFocus considers SOFIVA GENOMICS Co to be Modestly Overvalued.
Key valuation signals for ROCO:6615:
GF Score: 68 (near median its 10-year median of 63.00)
GF Value™: NT$30.93 vs. price of NT$34.90 (12.8% above fair value)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
